GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Asensus Surgical Inc (AMEX:ASXC) » Definitions » Return-on-Tangible-Asset

Asensus Surgical (Asensus Surgical) Return-on-Tangible-Asset : -184.50% (As of Mar. 2024)


View and export this data going back to 1991. Start your Free Trial

What is Asensus Surgical Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Asensus Surgical's annualized Net Income for the quarter that ended in Mar. 2024 was $-89.99 Mil. Asensus Surgical's average total tangible assets for the quarter that ended in Mar. 2024 was $48.77 Mil. Therefore, Asensus Surgical's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was -184.50%.

The historical rank and industry rank for Asensus Surgical's Return-on-Tangible-Asset or its related term are showing as below:

ASXC' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -220.42   Med: -109.78   Max: -51.92
Current: -116.1

During the past 13 years, Asensus Surgical's highest Return-on-Tangible-Asset was -51.92%. The lowest was -220.42%. And the median was -109.78%.

ASXC's Return-on-Tangible-Asset is ranked worse than
88.8% of 866 companies
in the Medical Devices & Instruments industry
Industry Median: -2.715 vs ASXC: -116.10

Asensus Surgical Return-on-Tangible-Asset Historical Data

The historical data trend for Asensus Surgical's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Asensus Surgical Return-on-Tangible-Asset Chart

Asensus Surgical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -202.33 -118.98 -53.71 -51.92 -91.03

Asensus Surgical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -84.84 -96.12 -100.09 -108.31 -184.50

Competitive Comparison of Asensus Surgical's Return-on-Tangible-Asset

For the Medical Devices subindustry, Asensus Surgical's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Asensus Surgical's Return-on-Tangible-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Asensus Surgical's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Asensus Surgical's Return-on-Tangible-Asset falls into.



Asensus Surgical Return-on-Tangible-Asset Calculation

Asensus Surgical's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-78.433/( (114.477+57.849)/ 2 )
=-78.433/86.163
=-91.03 %

Asensus Surgical's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-89.988/( (57.849+39.7)/ 2 )
=-89.988/48.7745
=-184.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


Asensus Surgical  (AMEX:ASXC) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Asensus Surgical Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Asensus Surgical's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Asensus Surgical (Asensus Surgical) Business Description

Traded in Other Exchanges
Address
1 TW Alexander Drive, Suite 160, Durham, NC, USA, 27703
Asensus Surgical Inc is a medical device company that digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy. It enables the use of advanced capabilities such as augmented intelligence, connectivity, and robotics in laparoscopy and seeks to address the current clinical, cognitive, and economic shortcomings in surgery. The Senhance Surgical System is the first machine vision system for use in robotic surgery, which is powered by the new Intelligent Surgical Unit that enables augmented intelligence in surgery and brings the benefits of digital laparoscopy to patients around the world. The company's single segment includes the research, development, and sale of medical device robotics to improve minimally invasive surgery.
Executives
Starling William N Jr director 2300 BUCKSKIN ROAD, POCATELLO ID 83201
Andrea Biffi director C/O SOFAR SPA, VIA FIRENZE 40, TREZZANO ROSA (MI) L6 20060
Elizabeth Kwo director C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
David Bruce Milne director ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108
Kevin J Hobert director 343 STATE STREET, ROCHESTER NY 14650
Fernando Anthony C. J. officer: Chief Technology Officer 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27560
Rampertab Shameze officer: EVP, Chief Financial Officer C/O ZOMEDICA PHARMACEUTICALS CORP., 3928 VARSITY DRIVE, ANN ARBOR MI 48108
Brett Farabaugh officer: Interim CFO 108 T.W. ALEXANDER DRIVE, RESEARCH TRIANGLE PARK NC 27709
Joseph P Slattery officer: EVP and CFO C/O TRANSENTERIX, INC., 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27560
Eric A Smith officer: Chief Commercial Officer 7 CALEB CIRCLE, SAN ANTONIO TX 78258
Todd Pope director, officer: President and CEO C/O TRANSENTERIX, 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27713
Willam N Kelley director MERCK & CO., INC., ONE MERCK DRIVE, WHITEHOUSE STATION X1 08889
Pfenniger Richard C Jr director 4400 BISCAYNE BLVD., MIAMI FL 33137
Sofar, S.p.a 10 percent owner VIA FIRENZE 40, TREZZANO ROSA L6 20060
Andrew N Schiff director, 10 percent owner PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022

Asensus Surgical (Asensus Surgical) Headlines

From GuruFocus